{rfName}

Indexed in

License and use

Citations

4

Altmetrics

Grant support

There is no funding to declare.

Analysis of institutional authors

Martinez, CarmenCorresponding AuthorCarcelero, EstherAuthorMagnano, LauraAuthorMozas, PabloAuthorFernandez-Aviles, FrancescAuthorSetoain, XavierAuthorRodriguez, SoniaAuthorEsteve, JordiAuthor

Share

Publications
>
Article

Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD

Publicated to:Hematological Oncology. 42 (5): e3299- - 2024-09-01 42(5), DOI: 10.1002/hon.3299

Authors: Martinez, Carmen; Carcelero, Esther; Gutierrez, Antonio; Sancho, Esther; Marti-Tutusaus, Josep Maria; Magnano, Laura; Mozas, Pablo; Fernandez-Aviles, Francesc; Antelo, Maria Gabriela; Setoain, Xavier; Rodriguez, Sonia; Esteve, Jordi

Affiliations

Abstract

Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.

Keywords

AbvdAbvd protocolAdultAdvanced cancerAgedAntineoplastic agentAntineoplastic combined chemotherapy protocolsArticleAutologous stem cell transplantationBleomycinBrentuximab vedotinCancer combination chemotherapyCancer immunotherapyCancer stagingCancer survivalChemotherapyClassical hodgkin lymphomaClinical articleCyclesDacarbazineDiagnostic imagingDoxorubicinDrug dose escalationDrug efficacyDrug therapyDrug withdrawalFebrile neutropeniaFemaleFirst-line chemotherapyFirst-line treatmentFirst‐line chemotherapyFollow upFollow-up studiesGemcitabineGranulocyte colony stimulating factorHodgkin diseaseHodgkin lymphomaHumanHumansLymphocyte-rich classical hodgkin lymphomaMaleMedical record reviewMiddle agedMixed cellularity hodgkin lymphomaMonoclonal antibody therapyMonotherapyMortalityMultiple cycle treatmentNeoplasm stagingNeurotoxicityNivolumabNodular sclerosis hodgkin lymphomaOverall response rateOverall survivalPathologyPePembrolizumabPeripheral neuropathyPositive pet interiPositive pet interimPositron emission tomographyPositron-emission tomographyProgression free survivalResponse-adapted therapyRetrospective studySalvage therapyTherapyTherapy escalationThird-line treatmentTreatment outcomeTreatment responseTrialVinblastineVinorelbine tartrateYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Hematological Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 118/322, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Oncology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Medicine (Miscellaneous).

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-05-31:

  • WoS: 2
  • Scopus: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-31:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 3.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 3 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 11.43.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 6 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Martínez Muñoz, Carmen) and Last Author (Esteve Reyner, Jordi).

the author responsible for correspondence tasks has been Martínez Muñoz, Carmen.